Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) EBT Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EBT Margin for 16 consecutive years, with 13.07% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 1262.0% to 13.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 14.06% through Dec 2025, up 517.0% year-over-year, with the annual reading at 14.06% for FY2025, 517.0% up from the prior year.
  • EBT Margin for Q4 2025 was 13.07% at Niagen Bioscience, down from 14.12% in the prior quarter.
  • The five-year high for EBT Margin was 25.7% in Q4 2024, with the low at 51.17% in Q3 2021.
  • Average EBT Margin over 5 years is 10.38%, with a median of 5.9% recorded in 2022.
  • The sharpest move saw EBT Margin crashed -2144bps in 2021, then skyrocketed 3612bps in 2023.
  • Over 5 years, EBT Margin stood at 29.98% in 2021, then soared by 77bps to 6.88% in 2022, then soared by 108bps to 0.54% in 2023, then skyrocketed by 4678bps to 25.7% in 2024, then tumbled by -49bps to 13.07% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 13.07%, 14.12%, and 12.01% for Q4 2025, Q3 2025, and Q2 2025 respectively.